Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.61 |
| ▸ | CNR1 | P21554 | 7/20 | 0.61 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736805 | 0.94 | CNR2 (0.58) | CNR2CNR1BRD4LIPGPOLB | |
| SCHEMBL2736850 | 0.94 | CNR2 (0.60) | CNR2CNR1BRD4LIPGPOLB | |
| SCHEMBL2736810 | 0.93 | CNR2 (0.56) | CNR2CNR1BRD4POLBPDE10A | |
| SCHEMBL2736847 | 0.92 | CNR2 (0.58) | CNR2CNR1BRD4LIPGPOLB | |
| SCHEMBL2736892 | 0.91 | CNR2 (0.54) | CNR2CNR1BRD4PDE10ALMNA | |
| SCHEMBL2736795 | 0.91 | CNR2 (0.54) | CNR2CNR1BRD4LIPGPOLB | |
| SCHEMBL2736877 | 0.90 | CNR2 (0.53) | CNR2CNR1BRD4PDE10A | |
| SCHEMBL2736826 | 0.89 | CNR2 (0.55) | CNR2CNR1BRD4POLBPDE10A | |
| SCHEMBL2736813 | 0.89 | CNR2 (0.52) | CNR2CNR1BRD4LIPGPOLB | |
| SCHEMBL2736861 | 0.89 | CNR2 (0.54) | CNR2CNR1BRD4POLBPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| EP-1477186-B1 | ANTIPRURITICS | SHIONOGI & CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-1477186-B1 | ANTIPRURITICS | SHIONOGI & CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20060052411-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | TADA YUKIO | 2006-03-09 | — | — | US | disclosed |
| US-6977266-B2 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2005-12-20 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040082619-A1 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1357111-A1 | PYRIDONE DERIVATIVE HAVING AFFINITY FOR CANNABINOID 2-TYPE RECEPTOR | SHIONOGI & CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | CNR2 1/4885CNR1 2/4885BRD4 152/4885 |
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | CNR2 2/4885CNR1 1/4885BRD4 389/4885 |
| US-20060052411-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | CNR2, CNR1, NPY2R | CNR2 1/4885CNR1 2/4885BRD4 115/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CNR2 2/4885CNR1 1/4885BRD4 446/4885 |
| US-20040082619-A1 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | CNR1, CNR2, NPY1R | CNR2 2/4885CNR1 1/4885BRD4 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.